[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-343982-en":59,"doc-seo-343982-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},343982,962075114101,"Seraphina","https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","c-MET and the immunological landscape of cancer - novel therapeutic strategies for enhanced anti-tumor immunity","Cellular mesenchymal-epithelial transition factor (c-MET), a receptor tyrosine kinase also known as HGFR, is analyzed for its central role in solid tumor biology and immune regulation. Co-expression of c-MET and PD-L1 in cancers is linked to prognosis and therapeutic resistance, driven by tumor and myeloid-derived suppressor cell interactions. HGF-mediated c-MET signaling promotes metabolic reprogramming, amino-acid depletion, and an immunosuppressive microenvironment. The review synthesizes clinical implications and emerging c-MET–focused immunotherapies, including CAR-based approaches and antibody modalities, to improve anti-tumor efficacy.","TYPE Review  \nPUBLISHED 27 November 2024 DOI 10.3389/fimmu.2024.1498391  \nOPEN ACCESS  \nEDITED BY  \nRemya Raja,  \nMayo Clinic Arizona, United States  \nREVIEWED BY  \nDafne Müller,  \nUniversity of Stuttgart, Germany Qiuping Xu,  \nSun Yat-sen Memorial Hospital, China  \n*CORRESPONDENCE  \nParham Jabbarzadeh Kaboli  \n [parham.kaboli@wum.edu.pl](parham.kaboli@wum.edu.pl);  \n [pjabbarzadeh@gmail.com](pjabbarzadeh@gmail.com)[ ](pjabbarzadeh@gmail.com)Abdessamad Zerrouqi  \n [abdessamad.zerrouqi@wum.edu.pl](abdessamad.zerrouqi@wum.edu.pl)  \nRECEIVED 06 October 2024  \nACCEPTED 04 November 2024  \nPUBLISHED 27 November 2024  \nCORRECTED 06 November 2025  \nCITATION  \nJabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z and Zerrouqi A (2024) c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. Front. Immunol. 15:1498391 .  \ndoi: 10.3389/fimmu.2024.1498391  \nCOPYRIGHT  \n© 2024 Jabbarzadeh Kaboli, Roozitalab, Farghadani, Eskandarian and Zerrouqi. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nc-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity  \nParham Jabbarzadeh Kaboli 1*, Ghazaal Roozitalab 2, Reyhaneh Farghadani 3, Zoya Eskandarian 4 and Abdessamad Zerrouqi 1*  \n1 Department of Biochemistry, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland,  \n2 Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran,  \n3Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor Darul Ehsan, Malaysia, 4 Research Institute Children ’s Cancer Center, and Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany  \nCellular mesenchymal-epithelial transition factor (c-MET), also known ashepatocyte growth factor receptor (HGFR), is a crucial receptor tyrosine kinase implicated in various solid tumors, including lung, breast, and liver cancers. The concomitant expression of c-MET and PD-L1 in tumors, such as hepatocellular carcinoma, highlights their prognostic signiﬁcance and connection to therapeutic resistance. Cancer-associated ﬁbroblasts and mesenchymal stromal cells produce hepatocyte growth factor (HGF), activating c-MET signaling in tumor cells and myeloid-derived suppressor cells (MDSC) . This activation leads to metabolic reprogramming and increased activity of enzymes like glutaminase (GLS), indoleamine 2,3-dioxygenase (IDO), and arginase 1 (ARG1), depleting essential amino acids in the tumor microenvironment that are vital for effector immune cell function. This review highlights the interplay between tumor cells and myeloidderived suppressor cells (MDSCs) that create an immunosuppressive environment while providing targets for c-MET-focused immunotherapy. It emphasizes the clinical implications of c-MET inhibition on the behavior of immune cells such as neutrophils, macrophages, T cells, and NK cells. It explores the potential of c-MET antagonism combined with immunotherapeutic strategies to enhance cancer treatment paradigms. This review also discusses the innovative cancer immunotherapies targeting c-MET, including chimeric antigen receptor (CAR) therapies, monoclonal antibodies, and antibody-drug conjugates, while encouraging the development of a comprehensive strategy that simultaneously tackles immune evasion and enhances anti-tumor efﬁcacy further to improve the clinical prognoses for patients with c-MET-positive malignancies. Despite the challenges and variability in efﬁcacy ac","cbCaivGncomrOqaV","https://ap.wps.com/l/cbCaivGncomrOqaV","pdf",8444342,28,"English","en",105,"# Introduction\n## c-MET as a receptor tyrosine kinase in tumors\n## c-MET signaling pathways and downstream effects\n## c-MET in therapeutic and immunotherapy resistance\n# Immunological interplay and therapeutic implications","[{\"question\":\"What is c-MET and why is it important in cancer?\",\"answer\":\"c-MET is a receptor tyrosine kinase (also called HGFR) implicated in multiple solid tumors. The review highlights its activation and downstream signaling as key drivers of cancer progression.\"},{\"question\":\"How does c-MET relate to PD-L1 and immune suppression?\",\"answer\":\"The document describes concomitant expression of c-MET and PD-L1 as relevant to prognosis and therapeutic resistance. It further links c-MET signaling to metabolic changes that contribute to an immunosuppressive tumor microenvironment.\"},{\"question\":\"What therapeutic strategies does the review discuss for enhancing anti-tumor immunity?\",\"answer\":\"It emphasizes c-MET inhibition and combination approaches with immunotherapies. The review also discusses innovative immunotherapies targeting c-MET, including CAR therapies, monoclonal antibodies, and antibody-drug conjugates.\"}]","c-MET and the immunological landscape of cancer - novel therapeutic strategies for enhanced anti-tumor immunity | PDF",1790052683,71,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a5184ea2e311a5c6422f342aea69ea7.webp",983,1389,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a09d820d1313d6e80be3a74e014d667.webp",982,1388,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e7ae4931040d39c8664d0f301973953.webp",981,1386,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3168c3f08b8ec44bebd357d1dd8602a.webp",980,1385,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"c-met-and-the-immunological-landscape-of-cancer-novel-therapeutic-strategies-for-enhanced-anti-tumor-immunity","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/c-met-and-the-immunological-landscape-of-cancer-novel-therapeutic-strategies-for-enhanced-anti-tumor-immunity/343982/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/c-met-and-the-immunological-landscape-of-cancer-novel-therapeutic-strategies-for-enhanced-anti-tumor-immunity/343982.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":136,"interactionType":137,"userInteractionCount":29},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"What is c-MET and why is it important in cancer?","Question",{"text":146,"@type":147},"c-MET is a receptor tyrosine kinase (also called HGFR) implicated in multiple solid tumors. The review highlights its activation and downstream signaling as key drivers of cancer progression.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How does c-MET relate to PD-L1 and immune suppression?",{"text":151,"@type":147},"The document describes concomitant expression of c-MET and PD-L1 as relevant to prognosis and therapeutic resistance. It further links c-MET signaling to metabolic changes that contribute to an immunosuppressive tumor microenvironment.",{"name":153,"@type":144,"acceptedAnswer":154},"What therapeutic strategies does the review discuss for enhancing anti-tumor immunity?",{"text":155,"@type":147},"It emphasizes c-MET inhibition and combination approaches with immunotherapies. The review also discusses innovative immunotherapies targeting c-MET, including CAR therapies, monoclonal antibodies, and antibody-drug conjugates.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790443132]